Regulation - Regulation, Almirall

Filter

Current filters:

RegulationAlmirall

Popular Filters

Sativex approved for MS in Switzerland

Sativex approved for MS in Switzerland

27-11-2013

UK-based GW Pharmaceuticals (AIM: GWP), which is focused on novel cannaboid therapeutics, has received…

AlmirallCNS DiseasesEuropeGW PharmaceuticalsPharmaceuticalRegulationSativex

Aclidinium and formoterol fixed dose combo for COPD filed in Europe by Almirall

04-11-2013

Spain’s largest drugmaker Almirall has filed a Marketing Authorization Application to the European…

aclidiniumAlmirallEuropeformoterolPharmaceuticalRegulationRespiratory and Pulmonary

Forest Labs and Almirall opt to delay US filing for combo COPD drug

15-08-2013

USA-based Forest Laboratories (NYSE: FRX) and Spain's largest drugmaker Almirall (ALM:MC) said late yesterday…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

IQWiG finds no added benefit proven for Constella in IBS

07-08-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

AlmirallConstellaEuropeGastro-intestinalsIronwood PharmaceuticalsPharmaceuticalPricingRegulation

First approved new class of IBS-C therapy, Constella, now available in Europe

13-06-2013

Spain's largest drugmaker Almirall (ALM: MC) and US partner Ironwood Pharmaceuticals, (Nasdaq: IRWD)…

AlmirallConstellaEuropeGastro-intestinalsIronwood PharmaceuticalsMarkets & MarketingPharmaceuticalRegulation

Almirall pays GW Pharma milestone on Sativex; reports 1st-qtr results

07-05-2013

UK-based GW Pharmaceuticals (AIM: GWP) says that it has received commercialization approval for its cannabinoid-based…

AlmirallEuropeFinancialGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

The solution for Spanish pharma companies lies abroad

13-03-2013

The pressure on the prices of medicines by Spanish government has seen the pharmaceutical market in Spain…

AlmirallEuropeFinancialGrifolsPharmaceuticalPricingRegulationZeltia

Added benefit of Almirall's aclidinium bromide is not proven, says Germany's IQWiG

10-01-2013

The drug aclidinium bromide, trade names Eklira, Bretaris from Spain's largest drugmaker Almirall (ALM:…

aclidiniumAlmirallBretaris GenuairEkliraEuropePharmaceuticalPricingRegulationRespiratory and Pulmonary

EMA backs Almirall's Constella; Bayer's Eylea recommended by CHMP

24-09-2012

The European Medicines Agency last Friday issued a batch of recommendations relating to marketing authorization…

AlmirallBayerConstellaEuropeEyleaGastro-intestinalsIronwood PharmaceuticalsNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

Almirall's aclidinium approved in Europe for COPD maintenance treatment

25-07-2012

Spain's leading drugmaker, Almirall (ALM: MC) says that the European Commission has granted marketing…

aclidiniumAlmirallBretaris GenuairEklira GenuairEuropeMenariniPharmaceuticalRegulationRespiratory and Pulmonary

US FDA backs Forest and Almirall's Tudorza Pressair to treat COPD

24-07-2012

US drugmaker Forest Laboratories (NYSE: FRX) and Spain's largest pharma firm Almirall (ALM: MC,) which…

AlmirallForest LaboratoriesNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Spanish reforms and generics hit Almirall's 1st-qtr; Sativex progress

09-05-2012

Spain's leading drugmaker Almirall (ALM: MC) has reported a 5.9% decrease in sales for the first quarter…

AlmirallEuropeFinancialGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

No proof of added benefit of Sativex, says German IQWiG

17-04-2012

In an early benefit assessment under to the German Act on the Reform of the Market for Medicinal Products…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalPricingRegulationSativex

US FDA delays approval of Almirall and Forest Laboratories' COPD drug

30-03-2012

The US Food and Drug Administration has said it will require a three-month extension to complete its…

aclidiniumAlmirallEkliraEuropeForest LaboratoriesLicensingMenariniNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Bayer and Algeta’s Alpharadin efficacy confirmed; Almirall to market Xarelto in Spain

13-02-2012

German drug major Bayer (BAY: DE) and Norwegian partner Algeta (OSE: ALGETA) announced that the survival…

AlgetaAlmirallAlpharadinBayerCardio-vascularEuropeMarkets & MarketingOncologyPharmaceuticalRegulationResearchXarelto

GW Pharma’s Sativex cleared in Austria

07-02-2012

The UK’s GW Pharmaceuticals’ (AIM: GWP) Sativex (delta-9-tetrahydrocannabinol (THC) and cannabidiol…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

US FDA accepts Ironwood and Forest’s NDA for IBS drug linaclotide; new data from Almirall

24-10-2011

US drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD) and Forest Laboratories (NYSE: FRX) said yesterday…

AlmirallForest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideNorth AmericaPharmaceuticalRegulationResearch

Nycomed to market Almirall’s Kestine in Southeast Asia markets; files for linaclotide in EU

30-09-2011

Swiss drug maker Nycomed, currently the subject of a 9.6 billion-euro takeover by Japan’s Takeda…

AlmirallAsia-PacificEuropeGastro-intestinalsLicensinglinaclotideNycomedPharmaceuticalRegulationRespiratory and Pulmonary

Back to top